Sign in
ORKA Stock Price, Chart, Stats & News
Oruka Therapeutics, Inc.
Save
Oruka Therapeutics, Inc. (ORKA) is a dividend-paying stock.
ORKA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -21.58% |
ROE | -25.30% |
D/E | 0.00x |
Interest coverage ratio | – |
ORKA valuation
P/E | – |
P/S | – |
P/B | 5.13x |
P/CF | -27.44x |
P/FCF | -18.84x |
P/OCF | -27.44x |
PEG | -0.76x |
EV multiple | -15.52x |
About
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.
Similar securities
Based on sector and market capitalization
Report issue